CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax.
Kour S, Rana S, Contreras JI, King HM, Robb CM, Sonawane YA, Bendjennat M, Crawford AJ, Barger CJ, Kizhake S, Luo X, Hollingsworth MA, Natarajan A.
Kour S, et al. Among authors: bendjennat m.
Mol Pharmacol. 2019 Oct;96(4):419-429. doi: 10.1124/mol.119.116855.
Mol Pharmacol. 2019.
PMID: 31467029
Free PMC article.